Startup Tiburio nabs Avrobio executive Kreher as CMO by Ben Adams Tuesday, March 12, 2019 Tiburio is wasting no time in getting its executives in order, nabbing Avrobio’s former chief medical officer Nerissa Kreher, M.D., as its own.
Avrobio posts encouraging update for Fabry gene therapy trials by Amirah Al Idrus Wednesday, February 6, 2019 The Cambridge, Massachusetts-based biotech announced updated data on Wednesday for two trials of its lentiviral-based, ex vivo gene therapy.
Avrobio slumps on Fabry gene therapy data by Phil Taylor Tuesday, October 2, 2018 Shares in Avrobio dropped after it reported results from the first three patients on its Fabry disease gene therapy, raising durability questions.
Aptinyx, Magenta lead IPO flurry ahead of summer lull by Phil Taylor Thursday, June 21, 2018 No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Atlas gene therapy startup Avrobio files for $86M IPO by Nick Paul Taylor Tuesday, May 29, 2018 The IPO would give Avrobio the means to trial gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer.
Avrobio pulls in $60M to push Fabry, Gaucher candidates through the clinic by Amirah Al Idrus Thursday, February 1, 2018 With the financing, Avrobio plans to push its pipeline through the clinic "as aggressively as possible."
